SCHEMBL6908331

SCHEMBL6908331

CCOC(=O)CN(C(C)=O)c1cccc(O)c1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.45
CYP3A4 P08684 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.43
TSHR P16473 1/20 0.41
GAA P10253 1/20 0.39
CA12 O43570 4/20 0.38
CA1 P00915 4/20 0.38
CA2 P00918 4/20 0.38
CA7 P43166 4/20 0.38
CA9 Q16790 4/20 0.38
CA14 Q9ULX7 4/20 0.38
HSD17B1 P14061 2/20 0.38
HSD17B2 P37059 2/20 0.38
USP2 O75604 1/20 0.38
LMNA P02545 1/20 0.38
KDM4E B2RXH2 2/20 0.38
NLRP3 Q96P20 2/20 0.38
MAPT P10636 1/20 0.37
TDP1 Q9NUW8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6907879 0.89 ALDH1A1 (0.45) ALDH1A1CYP3A4SMN1; SMN2TSHRGAA
SCHEMBL6903155 0.85 LMNA (0.45) ALDH1A1CYP3A4TSHRHSD17B1HSD17B2
SCHEMBL5807041 0.83 SMN1; SMN2 (0.60) ALDH1A1SMN1; SMN2TSHRGAAUSP2
SCHEMBL6907787 0.82 LMNA (0.48) ALDH1A1CYP3A4SMN1; SMN2TSHRGAA
SCHEMBL3662801 0.82 CA12 (0.47) ALDH1A1SMN1; SMN2TSHRGAACA12
SCHEMBL6905949 0.81 TTR (0.48) ALDH1A1CYP3A4SMN1; SMN2CA12CA1
SCHEMBL8415298 0.81 ALDH1A1 (0.63) ALDH1A1CYP3A4SMN1; SMN2TSHRCA12
SCHEMBL6905661 0.81 ALDH1A1 (0.46) ALDH1A1CYP3A4SMN1; SMN2TSHRGAA
SCHEMBL6907862 0.80 ALDH1A1 (0.47) ALDH1A1CYP3A4TSHRCA12CA1
SCHEMBL6227930 0.78 ALDH1A1 (0.53) ALDH1A1CYP3A4SMN1; SMN2TSHRCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6824786-B2 TOPICAL APPLYING COSMETIC YU RUEY J (US) 2004-11-30 US claimed
EP-1455734-A1 COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES Yu, Ruey J., Dr. (US) 2004-09-15 EP claimed
US-20030108496-A1 Compositions comprising phenyl-glycine derivatives YU RUEY J (US) 2003-06-12 US claimed
WO-2003045338-A1 COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES YU RUEY J (US) 2003-06-05 WO claimed
US-6824786-B2 TOPICAL APPLYING COSMETIC YU RUEY J (US) 2004-11-30 US disclosed
EP-1455734-A1 COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES Yu, Ruey J., Dr. (US) 2004-09-15 EP disclosed
US-20030108496-A1 Compositions comprising phenyl-glycine derivatives YU RUEY J (US) 2003-06-12 US disclosed
WO-2003045338-A1 COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES YU RUEY J (US) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030108496-A1 Compositions comprising phenyl-glycine derivatives GRHPR, ARL1, SUCLG1 ALDH1A1 1110/4885CYP3A4 4050/4885SMN1; SMN2 4727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.